Novakand Pharma AB (publ) (LARK) — Cash Flow Quality Index
Novakand Pharma AB (publ) (LARK) has a Cash Flow Quality Index of 0.10x as of September 2022. Operating cash flow of Skr379.00K is below net income of Skr3.95 Million, suggesting accrual-heavy earnings not yet converted to cash. For the full cash flow conversion analysis, see Novakand Pharma AB (publ) (LARK) cash flow conversion.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Novakand Pharma AB (publ) Cash Flow Quality Index (2021–2021)
Historical Cash Flow Quality Index for Novakand Pharma AB (publ) across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore LARK debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Quality Index for Novakand Pharma AB (publ) (2021–2021)
Year-by-year earnings quality comparison for Novakand Pharma AB (publ). Explore Novakand Pharma AB (publ) (LARK) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Quality Index | Operating CF (SEK) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 1.05x | Skr22.11 Million | Skr20.96 Million | — |